Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 4/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825614 | 0.86 | HPGD (0.46) | ADAM17CHRNA7GHSR | |
| SCHEMBL4825167 | 0.86 | CHRNA7 (0.40) | ADAM17CHRNA7CCKARCCKBRGHSR | |
| SCHEMBL4819428 | 0.86 | ADAM17 (0.44) | ADAM17CHRNA7CCKARCCKBRGHSR | |
| SCHEMBL4826756 | 0.82 | CHRNA7 (0.47) | CHRNA7CCKARCCKBRGHSR | |
| SCHEMBL8251025 | 0.82 | CNR2 (0.50) | CHRNA7GHSR | |
| SCHEMBL4822006 | 0.82 | CHRNA7 (0.47) | CHRNA7CCKARCCKBRGHSR | |
| SCHEMBL4823902 | 0.82 | CHRNA7 (0.47) | CHRNA7CCKARCCKBRGHSR | |
| SCHEMBL4826753 | 0.81 | CHRNA7 (0.45) | CHRNA7GHSR | |
| SCHEMBL5259022 | 0.81 | CHRNA7 (0.46) | CHRNA7GHSR | |
| SCHEMBL4825563 | 0.81 | CHRNA7 (0.46) | CHRNA7CCKARCCKBRGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | ADAM17 171/4885CHRNA7 3660/4885HCRTR1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.